FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
The COVID-19 Treatment Guidelines Panel. Statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. Available at:https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. Available at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. Available at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
Centers for Disease Control and Prevention (CDC). Influenza antiviral drug resistance. Available at: https://www.cdc.gov/flu/treatment/antiviralresistance.htm. Accessed February 2, 2022.
Centers for Disease Control and Prevention. COVID data tracker. Cases and deaths by vaccination status. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed February 2, 2022.
Hamel L, Kirzinger A, Muñana C, et al. KFF COVID-19 Vaccine Monitor December 2020. Kaiser Family Foundation. Available at:https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
Acknowledgement
References
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
The COVID-19 Treatment Guidelines Panel. Statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. Available at:https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/. Accessed February 2, 2022.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. Available at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
Centers for Disease Control and Prevention (CDC). Influenza antiviral drug resistance. Available at: https://www.cdc.gov/flu/treatment/antiviralresistance.htm. Accessed February 2, 2022.
- Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother. 2005; 49: 1671-1678https://doi.org/10.1128/AAC.49.5.1671-1678.2005
Centers for Disease Control and Prevention. COVID data tracker. Cases and deaths by vaccination status. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed February 2, 2022.
Hamel L, Kirzinger A, Muñana C, et al. KFF COVID-19 Vaccine Monitor December 2020. Kaiser Family Foundation. Available at:https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/. Accessed February 2, 2022.
- Genomic surveillance to combat COVID-19: challenges and opportunities.Lancet-Microbe. 2021; 2: e481-e484
- Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA.Nat Hum Behav. 2021; 5: 337-348https://doi.org/10.1038/s41562-021-01056-1
Article Info
Publication History
Footnotes
Funding: None.
Conflicts of Interest: JC, DGM report none. CHH reports that serving as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; to the Collaborative Institutional Training Initiative (CITI), legal counsel for Pfizer, the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as coinventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within Truist Investment Services, which has discretionary investment authority; and does not own any common or preferred stock in any pharmaceutical or medical device company.
Authorship: All authors had access to the data and a role in writing this manuscript.